References
- Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. 2012;122(8):2756–2762.
- Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012;380(9842):680–688.
- Nanthakumar CB, Hatley RJ, Lemma S, et al. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov. 2015;14(10):693–720.
- Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170(6):1807–1816.
- Hu B, Phan SH. Myofibroblasts. Curr Opin Rheumatol. 2013;25(1):71–77.
- Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028–1040.
- Jun JI, Lau LF. Resolution of organ fibrosis. J Clin Invest. 2018;128(1):97–107.
- Darby IA, Zakuan N, Billet F, et al. The myofibroblast, a key cell in normal and pathological tissue repair. Cell Mol Life Sci. 2016;73(6):1145–1157.
- Pakshir P, Noskovicova N, Lodyga M, et al. The myofibroblast at a glance. J Cell Sci. 2020;133:13.
- Bochaton-Piallat M-L, Gabbiani G, Hinz B. The myofibroblast in wound healing and fibrosis: answered and unanswered questions. F1000Research. 2016;5:752.
- Xie T, Liang J, Liu N, et al. Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis. J Clin Invest. 2016;126(8):3063–3079.
- Xie T, Wang Y, Deng N, et al., Single-cell deconvolution of fibroblast heterogeneity in Mouse pulmonary fibrosis. Cell Rep. 22(13): 3625–3640. 2018.
- Hinz B, Phan SH, Thannickal VJ, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180(4):1340–1355.
- Peyser R, MacDonnell S, Gao Y, et al. Defining the activated fibroblast population in lung fibrosis using single-cell sequencing. Am J Respir Cell Mol Biol. 2019;61(1):74–85.
- Tsukui T, Sun KH, Wetter JB, et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat Commun. 2020;11(1):1920.
- Sun KH, Chang Y, Reed NI, et al. alpha-Smooth muscle actin is an inconsistent marker of fibroblasts responsible for force-dependent TGFbeta activation or collagen production across multiple models of organ fibrosis. Am J Physiol Lung Cell Mol Physiol. 2016;310(9):L824–836.
- Yazdani S, Bansal R, Prakash J. Drug targeting to myofibroblasts: implications for fibrosis and cancer. Adv Drug Deliv Rev. 2017;121:101–116.
- Kramann R, Schneider RK. The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. Blood. 2018;131(19):2111–2119.
- Marriott S, Baskir RS, Gaskill C, et al. ABCG2pos lung mesenchymal stem cells are a novel pericyte subpopulation that contributes to fibrotic remodeling. Am J Physiol Cell Physiol. 2014;307(8):C684–698.
- El Agha E, Kramann R, Schneider RK, et al. Mesenchymal stem cells in fibrotic disease. Cell Stem Cell. 2017;21(2):166–177.
- El Agha E, Moiseenko A, Kheirollahi V, et al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell. 2017;20(4):571.
- Zepp JA, Zacharias WJ, Frank DB, et al. Distinct mesenchymal lineages and niches promote epithelial self-renewal and myofibrogenesis in the lung. Cell. 2017;170(6):1134–1148e1110.
- Lee JH, Tammela T, Hofree M, et al. Anatomically and functionally distinct lung mesenchymal populations marked by Lgr5 and Lgr6. Cell. 2017;170(6):1149–1163e1112.
- Adams TS, Schupp JC, Poli S, et al. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. Sci Adv. 2020;6(28):eaba1983.
- Hung CF, Wilson CL, Schnapp LM. Pericytes in the Lung. Adv Exp Med Biol. 2019;1122:41–58.
- Huang C, Ogawa R. The vascular involvement in soft tissue fibrosis-lessons learned from pathological scarring. Int J Mol Sci. 2020;21:7.
- Rock JR, Barkauskas CE, Cronce MJ, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A. 2011;108(52):E1475–1483.
- Hung C, Linn G, Chow YH, et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 2013;188(7):820–830.
- Sava P, Ramanathan A, Dobronyi A, et al. Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung. JCI Insight. 2017;2:24.
- Jolly MK, Ward C, Eapen MS, et al. Epithelial-mesenchymal transition, a spectrum of states: role in lung development, homeostasis, and disease. Dev Dyn. 2018;247(3):346–358.
- Chong SG, Sato S, Kolb M, et al. Fibrocytes and fibroblasts-where are we now. Int J Biochem Cell Biol. 2019;116:105595.
- Kleaveland KR, Velikoff M, Yang J, et al. Fibrocytes are not an essential source of Type I collagen during lung fibrosis. J Immunol. 2014;193(10):5229–5239.
- Zaslona Z, O’Neill LAJ. Cytokine-like roles for metabolites in Immunity. Mol Cell. 2020;78(5):814–823.
- Murphy MP, O’Neill LAJ. How should we talk about metabolism? Nat Immunol. 2020;21(7):713–715.
- Para R, Romero F, George G, et al. Metabolic reprogramming as a driver of fibroblast activation in pulmonaryfibrosis. Am J Med Sci. 2019;357(5):394–398.
- Zhao H, Dennery PA, Yao H. Metabolic reprogramming in the pathogenesis of chronic lung diseases, including BPD, COPD, and pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018;314(4):L544–L554.
- Liu RM, Liu G. Cell senescence and fibrotic lung diseases. Exp Gerontol. 2020;132:110836.
- D’Alessandro A, El Kasmi KC, Plecita-Hlavata L, et al. Hallmarks of pulmonary hypertension: mesenchymal and inflammatory cell metabolic reprogramming. Antioxid Redox Signal. 2018;28(3):230–250.
- Xie N, Tan Z, Banerjee S, et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am J Respir Crit Care Med. 2015;192(12):1462–1474.
- Yin X, Choudhury M, Kang JH, et al. Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-beta. Sci Signal. 2019;12:612.
- Cho SJ, Moon JS, Lee CM, et al. 1-dependent glycolysis is increased during aging-related lung fibrosis, and phloretin inhibits lung fibrosis. Am J Respir Cell Mol Biol. 2017;56(4):521–531.
- Rangarajan S, Bone NB, Zmijewska AA, et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat Med. 2018;24(8):1121–1127.
- Kottmann RM, Kulkarni AA, Smolnycki KA, et al. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-beta. Am J Respir Crit Care Med. 2012;186(8):740–751.
- Judge JL, Nagel DJ, Owens KM, et al. Prevention and treatment of bleomycin-induced pulmonary fibrosis with the lactate dehydrogenase inhibitor gossypol. PLoS One. 2018;13(5):e0197936.
- Goodwin J, Choi H, Hsieh MH, et al. Targeting hypoxia-inducible factor-1alpha/pyruvate dehydrogenase Kinase 1 axis by dichloroacetate suppresses bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2018;58(2):216–231.
- Stenmark KR, Tuder RM, El Kasmi KC. Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension. J Appl Physiol (1985). 2015;119(10):1164–1172.
- Plecita-Hlavata L, Tauber J, Li M, et al. Constitutive reprogramming of fibroblast mitochondrial metabolism in pulmonary hypertension. Am J Respir Cell Mol Biol. 2016;55(1):47–57.
- Li M, Riddle S, Zhang H, et al. Metabolic reprogramming regulates the proliferative and inflammatory phenotype of adventitial fibroblasts in pulmonary hypertension through the transcriptional corepressor C-terminal binding protein-1. Circulation. 2016;134(15):1105–1121.
- Zhang H, Wang D, Li M, et al. Metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary hypertension is regulated through a microRNA-124/PTBP1 (polypyrimidine tract binding protein 1)/pyruvate Kinase muscle axis. Circulation. 2017;136(25):2468–2485.
- Murtas G, Marcone GL, Sacchi S, et al. L-serine synthesis via the phosphorylated pathway in humans. Cell Mol Life Sci. 2020 Jun 27. DOI:10.1007/s00018-020-03574-z. Online ahead of print.
- Nigdelioglu R, Hamanaka RB, Meliton AY, et al. Transforming growth factor (TGF)-beta promotes de novo serine synthesis for collagen production. J Biol Chem. 2016;291(53):27239–27251.
- O’Leary EM, Tian Y, Nigdelioglu R, et al. TGF-beta promotes metabolic reprogramming in lung fibroblasts via mTORC1-dependent ATF4 activation. Am J Respir Cell Mol Biol. 2020 Jul 15. DOI:10.1165/rcmb.2020-0143OC. Online ahead of print.
- Selvarajah B, Azuelos I, Plate M, et al. mTORC1 amplifies the ATF4-dependent de novo serine-glycine pathway to supply glycine during TGF-beta1-induced collagen biosynthesis. Sci Signal. 2019;12:582.
- Schworer S, Berisa M, Violante S, et al. Proline biosynthesis is a vent for TGFbeta-induced mitochondrial redox stress. Embo J. 2020;39(8):e103334.
- Hamanaka RB, Nigdelioglu R, Meliton AY, et al. Inhibition of phosphoglycerate dehydrogenase attenuates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2018;58(5):585–593.
- Ge J, Cui H, Xie N, et al. Glutaminolysis promotes collagen translation and stability via alpha-Ketoglutarate-mediated mTOR activation and proline hydroxylation. Am J Respir Cell Mol Biol. 2018;58(3):378–390.
- Cui H, Xie N, Jiang D, et al. Inhibition of Glutaminase 1 attenuates experimental pulmonary fibrosis. Am J Respir Cell Mol Biol. 2019;61(4):492–500.
- Hamanaka RB, O’Leary EM, Witt LJ, et al. Glutamine metabolism is required for collagen protein synthesis in lung fibroblasts. Am J Respir Cell Mol Biol. 2019;61(5):597–606.
- Bai L, Bernard K, Tang X, et al. Glutaminolysis epigenetically regulates antiapoptotic gene expression in idiopathic pulmonary fibrosis fibroblasts. Am J Respir Cell Mol Biol. 2019;60(1):49–57.
- Bernard K, Logsdon NJ, Benavides GA, et al. Glutaminolysis is required for transforming growth factor-beta1-induced myofibroblast differentiation and activation. J Biol Chem. 2018;293(4):1218–1228.
- Hinz B, Lagares D. Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nat Rev Rheumatol. 2020;16(1):11–31.
- Horowitz JC, Thannickal VJ. Mechanisms for the resolution of organ fibrosis. Physiology (Bethesda). 2019;34(1):43–55.
- Glasser SW, Hagood JS, Wong S, et al. Mechanisms of lung fibrosis resolution. Am J Pathol. 2016;186(5):1066–1077.
- Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: molecular signals, cellular mechanisms and translational implications. Mol Aspects Med. 2019;65:2–15.
- Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.
- Kato K, Logsdon NJ, Shin YJ, et al. Impaired myofibroblast dedifferentiation contributes to nonresolving fibrosis in aging. Am J Respir Cell Mol Biol. 2020;62(5):633–644.
- Kheirollahi V, Wasnick RM, Biasin V, et al. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nat Commun. 2019;10(1):2987.
- Delbridge AR, Grabow S, Strasser A, et al. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16(2):99–109.
- Kuehl T, Lagares D. BH3 mimetics as anti-fibrotic therapy: unleashing the mitochondrial pathway of apoptosis in myofibroblasts. Matrix Biol. 2018;68-69:94–105.
- Lagares D, Santos A, Grasberger PE, et al. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Sci Transl Med. 2017;9:420.
- Bueno M, Calyeca J, Rojas M, et al. Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis. Redox Biol. 2020;33:101509.
- Parimon T, Yao C, Stripp BR, et al. Alveolar epithelial Type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. Int J Mol Sci. 2020;21:7.
- Meng X, Wang H, Song X, et al. The potential role of senescence in limiting fibrosis caused by aging. J Cell Physiol. 2020;235(5):4046–4059.
- Waters DW, Blokland KEC, Pathinayake PS, et al. Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018;315(2):L162–L172.
- Demaria M, Ohtani N, Youssef SA, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell. 2014;31(6):722–733.
- Li Y, Liang J, Yang T, et al. Hyaluronan synthase 2 regulates fibroblast senescence in pulmonary fibrosis. Matrix Biol. 2016;55:35–48.
- Cui H, Ge J, Xie N, et al. miR-34a inhibits lung fibrosis by inducing lung fibroblast senescence. Am J Respir Cell Mol Biol. 2017;56(2):168–178.
- Hecker L, Logsdon NJ, Kurundkar D, et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med. 2014;6(231):231ra247.
- Kato K, Hecker L. NADPH oxidases: pathophysiology and therapeutic potential in age-associated pulmonary fibrosis. Redox Biol. 2020;33:101541.
- Merkt W, Bueno M, Mora AL, et al. Targeting senescence in idiopathic pulmonary fibrosis. Semin Cell Dev Biol. 2020;101:104–110.
- Lehmann M, Korfei M, Mutze K, et al. Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo. Eur Respir J. 2017;50:2.
- Hohmann MS, Habiel DM, Coelho AL, et al. Quercetin enhances ligand-induced apoptosis in senescent idiopathic pulmonary fibrosis fibroblasts and reduces lung fibrosis in vivo. Am J Respir Cell Mol Biol. 2019;60(1):28–40.
- Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554–563.
- Schafer MJ, White TA, Iijima K, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. 2017;8:14532.